AC
CLDX icon

Athanor Capital’s Celldex Therapeutics CLDX Stock Holding History

Athanor Capital’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-20,767
Closed -$364K – 846
2020
Q4 		$364K Buy
20,767
+179
+0.9% +$3.22K 0.01% 534
2020
Q3 		$305K Buy
+20,588
New +$241K 0.01% 425

Other funds holding CLDX

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return

Athanor Capital's CLDX Position: Q1 2021 in Review

Athanor Capital sold out of Celldex Therapeutics (CLDX) in Q1 2021, closing a stake of 20,767 shares — an estimated $364K sold.

Athanor Capital first reported a position in CLDX in Q3 2020 and held it in 2 quarters. The position peaked at $364K in Q4 2020. 115 funds tracked by Wall St. Rank hold CLDX as of Q1 2021.

  • Athanor Capital reported no remaining Celldex Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Athanor Capital sold 20,767 Celldex Therapeutics shares in Q1 2021, an estimated $364K.
  • Athanor Capital first reported a position in Celldex Therapeutics in Q3 2020 and held it in 2 quarters.
  • Athanor Capital's Celldex Therapeutics position peaked at $364K in Q4 2020.
  • 115 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2021.

Based on Athanor Capital's 13F filing for Q1 2021, filed 14 May 2021.